or
forgot password
  • cancer clinical trials in oklahoma city, OK

  • Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Cervical Cancer, Precancerous Condition
    Study of Late-Occurring Complications in Childhood Cancer Survivors
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Cancer Survivor, Cardiovascular Complications, Hematopoietic/Lymphoid Cancer, Unspecified Childhood Solid Tumor, Protocol Specific
    Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
    University of Oklahoma
    Oklahoma City, Oklahoma 73190
    Breast Cancer
    Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Brain Tumor, Central Nervous System Tumor
    Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
    Cancer Care Associates/Oklahoma City
    Oklahoma City, Oklahoma 73112
    Chronic Lymphocytic Leukemia
    Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
    Oklahoma University Medical Center
    Oklahoma City, Oklahoma 73104
    Ovarian Cancer, Primary Peritoneal Cavity Cancer
    PANVACâ„¢-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
    University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104
    Pancreatic Cancer
    DNA Variations in the Gene in Young Patients With Wilms' Tumor
    Children's Hospital at Oklahoma University Medical Center
    Oklahoma City, Oklahoma 73104
    Kidney Cancer
    Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
    Oklahoma University Medical Center

    Trial Locations
    Oklahoma University Medical Center
    Cancer Care Associates - Mercy Campus
    Colorectal Cancer
    Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Localized Osteosarcoma, Metastatic Osteosarcoma
    Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Cervical Cancer
    Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Adenocarcinoma of the Colon, Stage II Colon Cancer
    Radiation Therapy in Treating Young Patients With Gliomas
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Brain Tumor, Central Nervous System Tumor
    Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Fallopian Tube Cancer, Ovarian Cancer
    Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Transitional Cell Carcinoma of the Bladder
    Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
    Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
    Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
    Oklahoma University Cancer Institute

    Trial Locations
    Oklahoma University Cancer Institute
    Cancer Care Associates - Mercy Campus
    Cancer Care Associates at Troy and Dollie Smith Cancer Center
    Colorectal Cancer
    ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
    GSK Investigational Site
    Oklahoma City, Oklahoma 73112
    Neoplasms, Breast
    Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Stage I Adrenocortical Carcinoma, Stage II Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
    Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Hereditary Breast/Ovarian Cancer (brca1, brca2), Osteoporosis, Ovarian Cancer
    ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Cervical Cancer
    Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Prostate Cancer
    Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
    University of Oklahoma Health Sciences Center

    Trial Locations
    University of Oklahoma Health Sciences Center
    Mercy Health Center
    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer
    Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
    University of Oklahoma Health Sciences Center

    Trial Locations
    University of Oklahoma Health Sciences Center
    Cancer Care Associates-Mercy
    Mercy Physicians of Oklahoma-Lakeside
    Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
    Radiation Therapy in Treating Patients With Stage II Prostate Cancer
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Prostate Cancer
    Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Kidney Cancer
    Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Neurofibrosarcoma, Childhood Synovial Sarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans, Localized Childhood Malignant Fibrous Histiocytoma of Bone, Metastatic Childhood Malignant Fibrous Histiocytoma of Bone, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
    Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Malignant Mesenchymoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
    Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Leukemia, Myelodysplastic Syndromes
    Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
    Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Stage III Wilms Tumor, Stage IV Wilms Tumor
    Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Untreated Childhood Medulloblastoma, Untreated Childhood Pineoblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
    University of Oklahoma Medical Center
    Oklahoma City, Oklahoma 73104
    Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
    Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
    Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
    Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Prostate Cancer
    Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
    University of Oklahoma Health Sciences Center

    Trial Locations
    University of Oklahoma Health Sciences Center
    Cancer Care Associates-Mercy
    Mercy Physicians of Oklahoma-Lakeside
    Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
    Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Ovarian Cancer
    Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
    VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Recurrent Endometrial Carcinoma
    ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
    Oklahoma State University Health Sciences Center
    Oklahoma City, Oklahoma 73104
    Anemia
    Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
    Oklahoma University Cancer Institute
    Oklahoma City, Oklahoma 73104
    Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
    A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
    Oklahoma University Health Sciences Center

    Trial Locations
    Oklahoma University Health Sciences Center
    Brian Lepley, D.O.
    Atopic Dermatitis